Loading...
In recent phase III studies, the ABT-450/r-based regimen — a coformulated pill of ABT-450/r-ombitasvir (a ritonavir-boosted protease inhibitor plus an NS5A inhibitor; once daily) plus dasabuvir (a nonnucleoside polymerase inhibitor; 250 mg twice daily) and ribavirin (1000–1200 mg daily) — yielded response rates >95% in patients with hepatitis C virus (HCV) genotype 1 infection (NEJM JW Gastroenterol Apr 15 2014).
In two industry-funded, phase III trials, investigators assessed the efficacy of the ABT-450/r-based regimen with and without ribavirin. They randomized treatment-naive patients with genotype 1a HCV infection (419 patients) and genotype 1b HCV infection (305 patients) without cirrhosis to receive the regimen with ribavirin or placeb…